Background Image
Table of Contents Table of Contents
Previous Page  1346 / 1498 Next Page
Information
Show Menu
Previous Page 1346 / 1498 Next Page
Page Background

Eligible patients:

CD20-postiive FL, WM, MZL,

SLL, MCL (elderly)

No previous treatment

Stage III or IV

R

A

N

D

O

M

I

s

E

Bendamustine-Rituximab (BR)

Bendamustine 90 mg/m

2

days 1-2

Rituximab 375 mg/m

2

day 1

CHOP-Rituximab (R-CHOP)

Cyclophosphamide 750 mg/m

2

day 1

Doxorubicin 50 mg/m

2

day 1

Vincristine 1.4 mg/m

2

day 1

Prednisone 100 mg/days days 1-5

Rituximab 375 mg/m

2

day 1

Primary objective

To prove the

non-inferiority of BR vs. R-CHOP

defined as a decrease of < 10% in progression-

free survival (PFS) after 3 years

Secondary objectives

Time to next treatment (TTNT), event-free survival (EFS), overall survival (OS)

Acute and late toxicities, infectious complications

Stem cell mobilization capacity in younger patients

(n = 549)

Mantle Cell Lymphomas (MCL): Updated Results from the StiL

NHL1 Study